In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
<p><strong>Question:</strong><br /> In patients with type 2 diabetes, do sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce risk for major kidney outcomes?</p><br /> <p><strong>Review Methods:</strong><br /> MEDLINE and Embase searc...
Main Authors: | Ng, SYA, Zhu, D, Herrington, WG |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American College of Physicians
2020
|
Similar Items
-
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
by: Mayne, KJ, et al.
Published: (2022) -
SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
by: Swetha R. Kanduri, et al.
Published: (2020-08-01) -
SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
by: Manuel Alfredo Podestà, et al.
Published: (2023-01-01) -
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
by: Yoshifumi Saisho
Published: (2020-05-01) -
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
by: Jennifer Matthews, et al.
Published: (2023-09-01)